Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions.
immunosuppression
non-small cell lung cancer
tumor microenvironment
tumor-associated macrophages
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
24
02
2021
revised:
26
03
2021
accepted:
07
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Non-small cell lung carcinoma (NSCLC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths. Immunotherapy with immune checkpoint inhibitors shows beneficial responses, but only in a proportion of patients. To improve immunotherapy in NSCLC, we need to map the immune checkpoints that contribute immunosuppression in NSCLC-associated immune cells and to identify novel pathways that regulate immunosuppression. Here, we investigated the gene expression profiles of intra-tumoral immune cells isolated from NSCLC patients and compared them to the expression profiles of their counterparts in adjacent healthy tissue. Transcriptome analysis was performed on macrophages, CD4
Identifiants
pubmed: 33918618
pii: cancers13081788
doi: 10.3390/cancers13081788
pmc: PMC8069596
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (NTNU) and St. Olavs University research funding
ID : Between 2014 and 2016
Références
Front Immunol. 2019 Jul 12;10:1563
pubmed: 31354719
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Br J Cancer. 2017 Nov 21;117(11):1644-1655
pubmed: 29016555
Am J Respir Cell Mol Biol. 2016 Jan;54(1):147-9
pubmed: 26274047
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Cancer Immunol Immunother. 2017 Aug;66(8):1079-1087
pubmed: 28638976
Eur Respir J. 2020 Feb 6;55(2):
pubmed: 32029641
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
J Immunother Cancer. 2016 Aug 16;4:48
pubmed: 27532023
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Immunity. 2019 Sep 17;51(3):573-589.e8
pubmed: 31474513
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Sci Rep. 2019 Oct 10;9(1):14611
pubmed: 31601953
Respir Res. 2018 Apr 18;19(1):66
pubmed: 29669565
Lung Cancer. 2018 Sep;123:127-135
pubmed: 30089583
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Oncotarget. 2017 Jul 5;8(44):75778-75796
pubmed: 29100268
J Immunol. 2014 Feb 1;192(3):851-7
pubmed: 24443508
FEBS Lett. 2015 Aug 4;589(17):2248-56
pubmed: 26149216
J Leukoc Biol. 2015 Jan;97(1):201-9
pubmed: 25359999
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Mol Cancer. 2019 May 14;18(1):94
pubmed: 31088471
Nat Rev Clin Oncol. 2020 Feb;17(2):73-74
pubmed: 31907372
Front Immunol. 2020 Feb 13;11:167
pubmed: 32117298
Nature. 2018 Oct;562(7728):605-609
pubmed: 30333625
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
Cancer Res. 2014 Dec 15;74(24):7250-9
pubmed: 25377469
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
Oncotarget. 2018 Feb 26;9(22):16248-16262
pubmed: 29662641
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Am J Transplant. 2016 May;16(5):1383-93
pubmed: 26601915
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Oncoimmunology. 2015 Mar 19;4(7):e1014242
pubmed: 26140237
Chest. 2008 Oct;134(4):783-788
pubmed: 18625675
Cancers (Basel). 2020 Dec 02;12(12):
pubmed: 33276569
Oncogene. 2010 Sep 2;29(35):4874-84
pubmed: 20581870
Front Immunol. 2019 Aug 27;10:2031
pubmed: 31507616
Oncoimmunology. 2020 Apr 7;9(1):1746554
pubmed: 32395395
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Cancer Immunol Immunother. 2019 Mar;68(3):341-352
pubmed: 30725206
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Curr Opin Immunol. 2016 Apr;39:1-6
pubmed: 26609943
Oncologist. 2019 Feb;24(Suppl 1):S31-S41
pubmed: 30819829
Adv Exp Med Biol. 2020;1223:155-165
pubmed: 32030689
Transl Oncol. 2020 Jan;13(1):17-24
pubmed: 31733591
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Front Immunol. 2020 Sep 02;11:1842
pubmed: 32983100
Nat Commun. 2018 May 18;9(1):1988
pubmed: 29777108
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563-1579
pubmed: 31575553
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3942-6
pubmed: 8632994
J Clin Invest. 2020 Jun 1;130(6):3137-3150
pubmed: 32125291
Front Immunol. 2018 Jul 16;9:1649
pubmed: 30061899